Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055809 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
A Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00055809: Completed Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor, sponsored by National Cancer Institute (NCI).
NCT00055809 is a Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, below the 96-participant average among 4 other Metastatic Gastrointestinal Carcinoid Tumor trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055809, a Phase 2 study of Metastatic Gastrointestinal Carcinoid Tumor and Recurrent Gastrointestinal Carcinoid Tumor, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL bevacizumab
- BIOLOGICAL PEG-interferon alfa-2b
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00055809 record still lists
NCT00055809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 96-participant average among 4 other Metastatic Gastrointestinal Carcinoid Tumor trials with a reported enrollment target (54% lower).
The record links to 3 conditions, with Metastatic Gastrointestinal Carcinoid Tumor appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00055809 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00055809 about?
NCT00055809 is a clinical study titled "Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors". This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells...
What is the current status of trial NCT00055809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2003-01.
What conditions does trial NCT00055809 study?
This clinical trial studies the following conditions: Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor.
What interventions are being tested in trial NCT00055809?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bevacizumab (BIOLOGICAL), PEG-interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055809?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055809 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Gastrointestinal Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia